| scholarly article | Q13442814 |
| P50 | author | Susan M. Ramin | Q110252023 |
| P2093 | author name string | Yang Xia | |
| Rodney E Kellems | |||
| Roxanna A Irani | |||
| Sean C Blackwell | |||
| Athar H Siddiqui | |||
| P2860 | cites work | Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia | Q28244090 |
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Is preeclampsia an autoimmune disease? | Q36050775 | ||
| Preeclampsia: the role of angiogenic factors in its pathogenesis | Q37512886 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. | Q52933863 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. | Q54782424 | ||
| Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia | Q56981959 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy | Q74090763 | ||
| Explaining and predicting preeclampsia | Q80223255 | ||
| Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression | Q81411178 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Pre-eclampsia | Q81446389 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| autoantibody | Q785022 | ||
| maternal health | Q6786626 | ||
| P304 | page(s) | 386-393 | |
| P577 | publication date | 2009-12-07 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | |
| P478 | volume | 55 |
| Q37082096 | 1,25(OH)2D3 Induces Placental Vascular Smooth Muscle Cell Relaxation by Phosphorylation of Myosin Phosphatase Target Subunit 1Ser507: Potential Beneficial Effects of Vitamin D on Placental Vasculature in Humans |
| Q27495953 | A Comprehensive Review of Hypertension in Pregnancy |
| Q27003069 | A leading role for the immune system in the pathophysiology of preeclampsia |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q92010061 | Adaptive Immunity in Hypertension |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q90305559 | Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism |
| Q36683260 | Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats |
| Q100408260 | Angiotensin II type 1 receptor antibodies in kidney transplantation: An evidence-based comprehensive review |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q34040304 | Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia |
| Q34347058 | Anti-idiotypic monobodies for immune response profiling |
| Q26828588 | Antibodies in the pathogenesis of hypertension |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q36050771 | Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling |
| Q34040357 | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia |
| Q47571875 | C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies |
| Q37699015 | Characterization of antibody specificities associated with preeclampsia |
| Q44235867 | Classification of cardiovascular time series based on different coupling structures using recurrence networks analysis. |
| Q38209381 | Clinical applications of biomarkers in preeclampsia |
| Q92759792 | Effect of a black cumin (Nigella sativa) ethanol extract on placental angiotensin II type 1-receptor autoantibody (AT1-AA) serum levels and endothelin-1 (ET-1) expression in a preeclampsia mouse model |
| Q36836373 | Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia |
| Q33740993 | Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia |
| Q34072217 | Exposure to AT1 receptor autoantibodies during pregnancy increases susceptibility of the maternal heart to postpartum ischemia-reperfusion injury in rats |
| Q50893991 | Fetal sex and the circulating renin-angiotensin system during early gestation in women who later develop preeclampsia or gestational hypertension. |
| Q38056887 | From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? |
| Q38151169 | Future therapies for pre-eclampsia: beyond treading water |
| Q36380039 | GPCRs as potential therapeutic targets in preeclampsia. |
| Q90685616 | Germ-line genetic variation in the immunoglobulin heavy chain creates stroke susceptibility in the spontaneously hypertensive rat |
| Q28078211 | Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair |
| Q36930454 | High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana |
| Q36244980 | Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation |
| Q37139722 | Identifying immune mechanisms mediating the hypertension during preeclampsia |
| Q37605722 | Increased risk of systemic lupus erythematosus in pregnancy-induced hypertension: A nationwide population-based retrospective cohort study |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q49351706 | Inflammatory and Immune System Markers. |
| Q38303854 | Limited evidence for calcium supplementation in preeclampsia prevention: a meta-analysis and systematic review |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q89454188 | Lipoxin A4 suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1 |
| Q64897032 | Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. |
| Q55004295 | Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. |
| Q46212939 | Maternal-Fetal rejection reactions are unconstrained in preeclamptic women |
| Q35540519 | Mechanisms of enhanced vascular reactivity in preeclampsia |
| Q54901493 | Molecular Mechanisms of Preeclampsia. |
| Q35175458 | Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit |
| Q90259719 | Placental Origins of Preeclampsia: Potential Therapeutic Targets |
| Q38705264 | Preeclampsia As Modulator of Offspring Health |
| Q38889590 | Preeclampsia and the brain: neural control of cardiovascular changes during pregnancy and neurological outcomes of preeclampsia |
| Q36965155 | Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines |
| Q33983395 | Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy |
| Q36537709 | RAS in Pregnancy and Preeclampsia and Eclampsia |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q37376964 | Recent advances in the understanding of the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q38637362 | Regulatory T-cells and preeclampsia: an overview of literature |
| Q33411571 | Renal function in normal and disordered pregnancy |
| Q35743816 | Renin angiotensin signaling in normal pregnancy and preeclampsia |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q57167914 | Residual Vascular Dysfunction in Women with a History of Preeclampsia |
| Q37206448 | The Prognostic Role of Angiotensin II Type 1 Receptor Autoantibody in Non-Gravid Hypertension and Pre-eclampsia: A Meta-analysis and Our Studies |
| Q47577568 | The agonistic autoantibodies to the angiotensin II type 1 receptor in pregnancies complicated by hypertensive disorders |
| Q33591058 | The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia |
| Q34683745 | The immunological basis of hypertension |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q38176651 | The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. |
| Q37088970 | The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia |
| Q64233038 | Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension |
| Q38493639 | Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings |
| Q37240779 | Transglutaminase is a Critical Link Between Inflammation and Hypertension |
| Q44770951 | Treg cells are negatively correlated with increased memory B cells in pre-eclampsia while maintaining suppressive function on autologous B-cell proliferation |
| Q38777852 | Understanding mechanisms of hypertension in systemic lupus erythematosus |
| Q48025132 | Upregulation of cathepsin C expression contributes to endothelial chymase activation in preeclampsia |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
| Q51294484 | Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension. |
Search more.